Ascendis Pharma (NASDAQ:ASND) Stock

ASCENDIS PHARMA A/S - ADR

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

Biotech

News

General

ASND

Ascendis Pharma Announces New Data Regarding Improvement In Growth And Bone Morphometry From Week 52 Of Its ApproaCH Trial Of TransCon CNP In Children With Achondroplasia.

- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE &amp; ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE).
The PaTH Forward Trial included a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension period through Week 266. Renal function was assessed by estimated glomerular filtration rate (eGFR). Bone turnover markers C-terminal telopeptide of type 1 collagen (CTx) and procollagen type 1 N-terminal propeptide (P1NP), as well as bone mineral density (BMD) measured by DXA scan, were assessed at baseline and regular intervals through Week 214. Safety assessments included 24-hour urine-calcium and treatment-emergent adverse events (TEAEs). At Week 214, 56 of the original 59 patients enrolled (95%) remained in the open-label extension portion of the trial.
At Week 214, nearly all patients (98%) continued to have normal albumin-adjusted serum calcium levels and 93% remained independent from conventional therapy (defined as taking &lt; 600mg/day of calcium and not taking active vitamin D). Bone turnover markers CTx and P1NP increased from the low end of normal at baseline, peaked by Week 26, then declined and remained stable above baseline levels through Week 214. The data also showed continued improvement in skeletal dynamics, with BMD remaining within age- and sex-matched norms. In addition, at Week 214, most participants (67.8%) had a clinically meaningful (≥ 5&nbsp;mL/min/1.73 m2) increase in eGFR from baseline, with changes in eGFR evident at Week 4.
In the trial, TransCon PTH treatment was generally well-tolerated, with no new safety signals identified. TEAEs were mostly mild or moderate and no serious TEAEs or discontinuations were related to study drug.
"We set out to address the underlying cause of disease and are pleased to see this long-term data reinforcing the safety profile and durability of response in patients treated with TransCon PTH, including sustained normalization of skeletal dynamics and significant and sustained improvements in kidney function," said&nbsp;Aimee Shu,&nbsp;M.D.&nbsp;Executive Vice President of Endocrine &amp; Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma.

Ascendis Pharma Announces New Data From Week 214 Of Its Phase 2 Path Forward Trial Showing That Long-Term Treatment With TransCon PTH Continued To Provide A Durable Response In Adults With Hypoparathyroidism

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $200 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $200 Price Target

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 21.51% on an annualized basis producing an average annual return of 32.45%. Currently, Ascendis Pharma has a market capitalization of $10.26 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $68,514.06 today based on a price of $170.60 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746540918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years

Events

AscendisTto Share Data From Hypoparathyroidism, Achondroplasia, And Growth Hormone Deficiency Programs During ESPE & ESE 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Vikram Purohit upgraded the rating for Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) from Equal-Weight to Overweight and raised the price target from $180 to $250. Ascendis Pharma shares closed at $172.06 on Friday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) from Hold to Buy and boosted the price target from $54 to $67. Worthington Enterprises shares closed at $51.99 on Friday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Stephen Bersey upgraded Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Reduce to Hold and raised the price target from $77 to $99. Twilio shares closed at $100.11 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst John Ivankoe upgraded the rating for The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) from Neutral to Overweight but lowered the price target from $17 to $15. Wendy&#8217;s shares closed at $12.55 on Friday. <a href="https://www.benzinga.com/quote/WEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Aaron Kessler upgraded Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from Neutral to Buy and announced a $165 price target. Reddit shares closed at $113.83 on Friday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWLO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png" alt="" class="wp-image-901223" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

RDDT

TWLO

This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Morgan Stanley analyst Vikram Purohit upgrades Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) from Equal-Weight to Overweight and raises the price target from $180 to $250.

Morgan Stanley Upgrades Ascendis Pharma to Overweight, Raises Price Target to $250

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $205 to $210.

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $210

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $200 to $245.

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $245

Wedbush analyst Yun Zhong maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $181 to $212.

Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $212

Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and raises the price target from $260 to $280.

Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $280

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported quarterly losses of $(1.66) per share which missed the analyst consensus estimate of $(1.46) by 13.7 percent. This is a 33.6 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $106.16 million which beat the analyst consensus estimate of $94.64 million by 12.17 percent. This is a 1.94 percent increase over sales of $104.15 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Ascendis Pharma Q1 EPS $(1.66) Misses $(1.46) Estimate, Sales $106.16M Beat $94.64M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ascendis Pharma to report an earnings per share (EPS) of $-1.51.
The announcement from Ascendis Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.52 in the last quarter, leading to a 12.96% increase in the share price on the following day.
Here's a look at Ascendis Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.20</td>
<td>-1.52</td>
<td>-1.56</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.68</td>
<td>-1.89</td>
<td>-2.06</td>
<td>-2.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>2.0%</td>
<td>-11.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Ascendis Pharma were trading at $166.58 as of April 29. Over the last 52-week period, shares are up 18.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ASND/earnings">To track all earnings releases for Ascendis Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Ascendis Pharma's Earnings Potential

RBC Capital analyst Luca Issi initiates coverage on Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform rating and announces Price Target of $205.

Initiation

RBC Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $205

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 45.5% on an annualized basis producing an average annual return of 55.38%. Currently, Ascendis Pharma has a market capitalization of $9.32 billion. 
Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 10 years ago, it would be worth $81,183.25 today based on a price of $155.06 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744747219_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.

Ascendis Submits New Drug Application To FDA For TransCon CNP For Treatment Of Children With Achondroplasia.

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 9.48% since its last report. The company recently reported that it has 4.38 million shares sold short, which is 8.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743002120_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 5.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ascendis Pharma's Recent Short Interest

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 20.52% on an annualized basis producing an average annual return of 31.71%. Currently, Ascendis Pharma has a market capitalization of $10.13 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $6,400.59 today based on a price of $168.50 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742921108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today

JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $168 to $200.

JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $200

Press Releases

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Health Care

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

Comments

Ascendis Pharma

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL